Citation Details
Sleeping Beauty Transposon-mediated Engineering of Human Primary T Cells for Therapy of CD19(+) Lymphoid Malignancies
| Authors |  Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S, Lees CJ, Li ZZ, Milone M, Levine BL, Tolar J, June CH, Scott McIvor R, Wagner JE, Blazar BR, Zhou X |
| In | Mol Ther (2008) 16(3): 580-9 |
| Cells used in publication | T cell, unstim., human Human unstimulated T cells Blood/Immune Cells Primary Cells Species: human Tissue Origin: blood |
| Related cells | T cell, stim., human |
| Substrate | plasmid (general) |
| Substrate Description | transposon/SB transpoase plasmid |
| Applications | Stable TransfectionCo-Transfection |
| Topics | Diseases (e.g. HIV)Intercellular interaction/communication |
| Research Areas | Cancer Research/Cell BiologyImmunology / Hematology |
| Relevant Products |  Nucleofector Device Human T Cell Nucleofector Kit |
Nucleofection Experiments
Mononuclear cells from PB or UCB, or CD3 bead-purified UCB T cells (5x10^6 cells) were nucleofected with a mixture of 5 µg SB-CD19 CAR transposon toghether with 15 µg of SB10 transpoase plasmid. After sorting using Rituxan about 85 % of cells were CAR positive, and 70-90 % cell recovery of the engineered PBL and UCB can be achieved.
Open PubMed page for this citation
Back to Citation List
